Author:
Aparicio T.,Boige V.,Sabourin J.-C.,Crenn P.,Ducreux M.,Le Cesne A.,Bonvalot S.
Subject
Oncology,General Medicine,Surgery
Reference17 articles.
1. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors;Demetri;N Engl J Med,2002
2. Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target
3. Comparison of two doses of imatinib for the treatment of advanced gastro intestinal stromal tumour: interim results of a randomised phase II study from the EORTC-STBSG, ISG, AGITG;Verveij;Proc ASCO,2003
4. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors;Singer;J Clin Oncol,2002
5. The effect of surgery and grade on outcome of gastrointestinal stromal tumors;Pierie;Arch Surg,2001
Cited by
123 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献